Bartlomiej Zerek

Title: Bartlomiej Zerek: Innovator in Anticancer Research

Introduction

Bartlomiej Zerek is a notable inventor based in Dabrowa, Poland. He has made significant contributions to the field of cancer research through his innovative work on anticancer fusion proteins. His dedication to advancing medical science is evident in his patented inventions.

Latest Patents

Zerek holds a patent for an anticancer fusion protein comprising TRAIL. This fusion protein, particularly recombinant, includes a functional fragment of the soluble hTRAIL protein sequence, beginning with an amino acid at a position not lower than hTRAIL95 or a sequence with at least 70% homology. The protein also features a pro-apoptotic effector peptide sequence attached at the C-terminus and/or N-terminus of the hTRAIL domain. This innovative fusion protein demonstrates anticancer activity and includes the nucleotide sequence coding for the protein, an expression vector, and a host cell for its preparation. The use of this fusion protein is aimed at treating various cancer diseases.

Career Highlights

Bartlomiej Zerek is associated with Adamed Sp. z o.o., where he continues to work on groundbreaking research in the field of oncology. His contributions have been instrumental in developing new therapeutic strategies for cancer treatment.

Collaborations

Zerek collaborates with esteemed colleagues, including Jerzy Szczepan Pieczykolan and Sebastian Dominik Pawlak. Their combined expertise enhances the research and development efforts in anticancer therapies.

Conclusion

Bartlomiej Zerek's innovative work in developing anticancer fusion proteins showcases his commitment to improving cancer treatment options. His contributions to the field are significant and reflect the potential for advancements in medical science.